Researchers Identify 4 Predictors of Transition to Chronic Opioid Use Based on Readily Available Opioid Regimen and Patient Factors
Access Market Intelligence Introduces Online Glossary of Common Drug Related Terms and Acronyms as e-Book
Succeeding in today’s crowded healthcare market often requires that associations align with like-minded organizations to achieve their goals. It is this realization that has led to a strategic partnership between The Lynx Group and the National Association of Specialty Pharmacy (NASP).
IMBRUVICA™ Approved For Previously Treated Chronic Lymphocytic Leukemia; Immediately Available Through Onco360®
Mekinist™ (trametinib) & Tafinlar® (dabrafenib) Approved In Combination; Both Limited Distribution Products Immediately Available Via Onco360®
PharMerica and Onco360 Finalize Strategic Investment; Establish First National Oncology Pharmacy and Care Management Platform
leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, and Onco360, the largest independent provider of oncology pharmacy services in the United States, today announced that the companies have entered into a definitive agreement under which PharMerica has acquired a significant minority stake of Onco360.
Results 1 - 7 of 7